Personalized Sequence for Thoracic, Esophageal, and H&N Cancer
Sponsor
Samsung Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT02299622
Collaborator
(none)
200
1
121
1.7
Study Details
Study Description
Brief Summary
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information Therefore, a big data of genome-clinical information is important.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(PFS, duration of response and overall survival) of patients with advanced cancer, the investigators are going to take a fresh tissue of patients and process molecular profiling.
Study Design
Study Type:
Observational
Anticipated Enrollment
:
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (PerSeq: Personalized Sequence)
Study Start Date
:
Nov 1, 2013
Anticipated Primary Completion Date
:
Nov 1, 2022
Anticipated Study Completion Date
:
Dec 1, 2023
Outcome Measures
Primary Outcome Measures
- the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation) [3 years]
The pattern of the tumor's molecular profiling in advanced thoracic (lung, esophagus, or tthymic) cancer
Eligibility Criteria
Criteria
Ages Eligible for Study:
21 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- metastatic, histologically confirmed NSCLC, head & Neck Cancer, Esophageal cancer
Exclusion Criteria:
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Samsung Medical Center | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Samsung Medical Center
Investigators
- Principal Investigator: Keunchil Park, Samsung Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Keunchil Park,
Professor,
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT02299622
Other Study ID Numbers:
- 2013-10-112
First Posted:
Nov 24, 2014
Last Update Posted:
Mar 19, 2021
Last Verified:
Mar 1, 2021
Additional relevant MeSH terms: